Table 1 |
|||
|
Main outcomes of the BLISS-52 and BLISS-76 trials |
|||
|
Belimumab 10 mg/kg (%) |
Belimumab 1 mg/kg (%) |
Placebo (%) |
|
|
|
|||
|
SRI response rate at 52 weeks (BLISS-52) |
58 (P = 0.0006) |
51 (P = 0.0129) |
44 |
|
SRI response rate at 52 weeks (BLISS-76) |
43.2 (P = 0.017) |
40.6 (P = 0.089) |
33.5 |
|
SRI response rate at 76 weeks (BLISS-76) |
38.5 (P = 0.13) |
39.1 (P = 0.11) |
32.4 |
|
Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-52) |
19 (P = 0.0526) |
21 (P = 0.025) |
12 |
|
Prednisone dose reduced ≥25%, to ≤7.5% mg/day during weeks 40 to 52 (BLISS-76) |
17.5 (P >0.05) |
19.2 (P >0.05) |
12.7 |
|
|
|||
|
SRI, Systemic Lupus Erythematosus Responder Index. |
|||
|
Boneparth and Davidson Arthritis Research & Therapy 2012 14(Suppl 4):S2 doi:10.1186/ar3920 |
|||